Background: Artemisinin derivatives are the main drugs used for the treatment of uncomplicated malaria. Although these drugs remain the most powerful anti-parasitic agents available, there is now evidence for parasite resistance to artesunate, the most widely used artemisinin derivative [1]. This finding provides motivation for conducting more pharmacokinetic-pharmacodynamic (PK-PD) studies of artesunate to monitor its […]
Kris Jamsen
- Model Answers Pty Ltd
Author Archive | Kris Jamsen
Optimal designs for population pharmacokinetic studies of the partner drugs administered with artemisinin derivatives
January 28, 2011
Authors Kris M Jamsen (1), Stephen B Duffull (2), Joel Tarning (3,4), Niklas Lindegardh (3,4), Nicholas J White (3,4), Julie A Simpson (1)
Affiliations (1) Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, School of Population Health, The University of Melbourne, Melbourne, Australia, (2) School of Pharmacy, The University of Otago, Dunedin, New Zealand, (3) Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand, (4) Centre for Tropical Medicine, Churchill Hospital, Oxford, UK
Presentation type Oral
Background: The World Health Organization recommends artemisinin-based combination therapy (ACT) as first line treatment for uncomplicated falciparum malaria1. ACT consists of a highly effective but short lived artemisinin derivative and a less effective but longer lasting partner drug(s). We have recently proposed optimal designs for future population pharmacokinetic studies of the main artemisinin derivative (Artesunate), […]
Optimal designs for population pharmacokinetic studies of a drug with large assay variability for patients with restrictive sampling schedules
January 14, 2009
Authors Kris M Jamsen (1), Julie A Simpson (1), Joel Tarning (3), Niklas Lindegardh (3), Nicholas J White (3,4), Stephen Duffull (2)
Affiliations (1) Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, School of Population Health, The University of Melbourne, Victoria 3010, Australia, (2) School of Pharmacy, The University of Otago, PO Box 913, Dunedin, New Zealand, (3) Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, (4) Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK
Presentation type Poster
Objective: This work aimed to determine an optimal design for patients with restrictive sampling schedules who received a drug* that displays huge assay variability, is rapidly absorbed and has a very short elimination half-life. Methods: Rich data from 20 patients were modelled in R (using nlme) to determine the structural pharmacokinetic (PK) model, PK parameters, inter-patient and […]